- Report
- May 2024
- 898 Pages
Global
From €5373EUR$5,600USD£4,646GBP
- Report
- January 2024
- 285 Pages
Global
From €9115EUR$9,500USD£7,882GBP
- Report
- January 2024
- 180 Pages
Global
From €7196EUR$7,500USD£6,223GBP
- Drug Pipelines
- July 2023
- 139 Pages
Global
From €10550EUR$10,995USD£9,122GBP
- Report
- April 2021
- 127 Pages
Global
From €10550EUR$10,995USD£9,122GBP
- Report
- April 2018
Global
From €959EUR$1,000USD£830GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£415GBP
- Report
- January 2019
- 35 Pages
Global
From €959EUR$1,000USD£830GBP
Requip (ropinirole) is a dopamine agonist used to treat symptoms of Parkinson's disease and restless legs syndrome. It is a member of the non-ergoline dopamine agonist class of drugs, which are used to treat Parkinson's disease and other movement disorders. Requip is also used to treat symptoms of depression and anxiety. It works by increasing the amount of dopamine in the brain, which helps to improve movement and reduce symptoms of Parkinson's disease.
Requip is a popular drug in the Central Nervous System (CNS) drug market. It is used to treat a variety of neurological conditions, including Parkinson's disease, restless legs syndrome, and depression. It is also used to treat symptoms of anxiety. Requip is generally well-tolerated and has few side effects.
The CNS drug market is a large and growing market, with many different drugs available to treat a variety of neurological conditions. Requip is one of the most popular drugs in this market, due to its effectiveness and safety profile.
Some companies in the Requip market include GlaxoSmithKline, Pfizer, and Novartis. Show Less Read more
